Top

Published in:

01-06-2013 | Review Article

Side effects of TNF-α blockers in patients with psoriatic arthritis: evidences from literature studies

Authors: Rosario Peluso, Giovanni Cafaro, Alessandro Di Minno, Salvatore Iervolino, Pasquale Ambrosino, Gelsy Lupoli, Matteo Nicola Dario Di Minno

Published in: Clinical Rheumatology | Issue 6/2013

Abstract

Psoriatic arthritis is an inflammatory rheumatic disorder, which occurs in patients with skin and/or nail psoriasis. In psoriatic arthritis, the importance of biologic mediators modulating inflammatory reaction, such as tumor necrosis factor, and the knowledge on their role in the pathogenesis of psoriatic arthritis influence the therapeutic choices. In the last years, the introduction of biologic drugs has greatly changed the treatment of psoriasis and psoriatic arthritis. In fact, tumor necrosis factor-α blockers demonstrated an effective action in the treatment of both skin and joint manifestations of psoriatic arthritis, but they have some adverse effects. The aim of this review is to revisit the literature data on adverse effects of tumor necrosis factor-α blockers in patients with psoriatic arthritis.

Scarpa R, Peluso R, Atteno M (2007) Clinical presentation of psoriatic arthritis. Reumatismo 59(1):49–51PubMed

Helliwell PS (2009) Established psoriatic arthritis: clinical aspects. J Rheumatol 36(83):21–23

Scarpa R, Cosentini E, Manguso F, Oriente A, Peluso R, Atteno M, Ayala F, D'Arienzo A, Oriente P (2003) Clinical and genetic aspects of psoriatic arthritis "sine psoriasis". J Rheumatol 30(12):2638–2640PubMed

Scarpa R, Cuocolo A, Peluso R, Atteno M, Gisonni P, Iervolino S, Di Minno MN, Nicolai E, Salvatore M, del Puente A (2008) Early psoriatic arthritis: the clinical spectrum. J Rheumatol 35(1):137–141PubMed

Scarpa R, Atteno M, Costa L, Peluso R, Iervolino S, Caso F, Del Puente A (2009) Early psoriatic arthritis. J Rheumatol Suppl 83:26–27PubMedCrossRef

Wright V, Moll JMH (1976) Seronegative polyarthritis. North Holland Publishing Company, Amsterdam

Wright V (1978) Seronegative polyarthritis: a unified concept. Arthritis Rheum 21:619–633PubMedCrossRef

Mease P, Goffe BS (2005) Diagnosis and treatment of psoriatic arthritis. J Am Acad Dermatol 52(1):1–19PubMedCrossRef

Gladman DD, Antoni C, Mease P, Clegg DO, Nash P (2005) Psoriatic arthritis: epidemiology, clinical features, course, and outcome. Ann Rheum Dis 64(2):14–17

10.

Krueger GG (2002) Clinical features of psoriatic arthritis. Am J Manag Care 8(6):60–70

11.

Tobin AM, Kirby B (2005) TNF alpha inhibitors in the treatment of psoriasis and psoriatic arthritis. Bio Drugs 19(1):47–57

12.

Atteno M, Peluso R, Costa L, Padula S, Iervolino S, Caso F, Sanduzzi A, Lubrano E, Del Puente A, Scarpa R (2010) Comparison of effectiveness and safety of infliximab, etanercept, and adalimumab in psoriatic arthritis patients who experienced an inadequate response to previous disease-modifying antirheumatic drugs. Clin Rheumatol 29(4):399–403PubMedCrossRef

13.

Joyau C, Veyrac G, Dixneuf V, Jolliet P (2012) Anti-tumour necrosis factor alpha therapy and increased risk of de novo psoriasis: is it really a paradoxical side effect? Clin Exp Rheumatol 30(5):700–706PubMed

14.

Nagy G, Lukács K, Sziray A, Fazekas K, Florián A, Tamási L, Károlyi Z (2011) Adverse events during biological therapy—focusing on dermatological side-effects. Orv Hetil 152(6):212–220PubMedCrossRef

15.

Kirshen C, Kanigsberg N (2009) Alopecia areata following adalimumab. J Cutan Med Surg 13(1):48–50PubMed

16.

Marasini B, Cozzaglio L, Belloli L, Massarotti M, Ughi N, Pedrazzoli P (2011) Metastatic melanoma in a young woman treated with TNF-alpha inhibitor for psoriatic arthritis: a case report. Curr Drug Saf 6(4):275–276PubMedCrossRef

17.

Lee HH, Song IH, Friedrich M, Gauliard A, Detert J, Röwert J, Audring H, Kary S, Burmester GR, Sterry W, Worm M (2007) Cutaneous side-effects in patients with rheumatic diseases during application of tumour necrosis factor-alpha antagonists. Br J Dermatol 156(3):486–491PubMedCrossRef

18.

Zidi I, Bartegi A, Ben AN (2011) Dermatologic adverse events: golimumab, friend or foe? Pharmazie 66(1):5–10PubMed

19.

Dixon WG, Watson K, Lunt M, Hyrich KL, Silman AJ, Symmons DP, British Society for Rheumatology Biologics Register (2006) Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum 54(8):2368–2376PubMedCrossRef

20.

Tsiodras S, Samonis G, Boumpas DT, Kontoyiannis DP (2008) Fungal infections complicating tumor necrosis factor blockade therapy. Mayo Clin Proc 83:181–194PubMed

21.

Kim SY, Solomon DH (2010) Tumor necrosis factor blockade and the risk of viral infection. Nat Rev Rheumatol 6(3):165–174PubMedCrossRef

22.

Strangfeld A, Listing J, Herzer P, Liebhaber A, Rockwitz K, Richter C, Zink A (2009) Risk of herpes zoster in patients with rheumatoid arthritis treated with anti-TNF-alpha agents. JAMA 301(7):737–744PubMedCrossRef

23.

Suwannalai P, Auethavekiat P, Udomsubpayakul U, Janvitayanujit S (2009) The infectious profiles of anti-tumor necrosis factor agents in a Thai population: a retrospective study a the university-based hospital. Int J Rheum Dis 12(2):118–124PubMedCrossRef

24.

Lydakis C, Ioannidou D, Koumpa I, Giannikaki E, Thalassinos E, Krasoudaki E, Miyakis S (2012) Development of lepromatous leprosy following etanercept treatment for arthritis. Clin Rheumatol 31(2):395–398PubMedCrossRef

25.

Kouba M, Rudolph SE, Hrdlicka P, Zuber MA (2012) Hepatitis-B reactivation during treatment with tumor necrosis factor-α blocker adalimumab in a patient with psoriasis arthritis. Dtsch Med Wochenschr 137(1–2):23–26PubMed

26.

Chung SJ, Kim JK, Park MC, Park YB, Lee SK (2009) Reactivation of hepatitis B viral infection in inactive HBsAg carriers following anti-tumor necrosis factor-alpha therapy. J Rheumatol 36(11):2416–2420PubMedCrossRef

27.

Lioté H, Lioté F (2011) Role for interferon-gamma release assays in latent tuberculosis screening before TNF-α antagonist therapy. Joint Bone Spine 78(4):352–357PubMedCrossRef

28.

Zimmerli L, Nüesch R, Elzi L (1994) Update on tuberculosis: interferon-gamma assays. Praxis (Bern 1994) 96(51–52):2051–2057

29.

Sanduzzi A, Bocchino M, Atteno M, Costa L, Ponticiello A, Matarese A, Spanò A, Bruner V, Peluso R, Aquino MM, Del Puente A, Scarpa R (2012) Screening and monitoring of latent tubercular infection in patients taking tumor necrosis factor-α blockers for psoriatic arthritis. J Rheumatol Suppl 89:82–85PubMedCrossRef

30.

Chang MB, Sri JC, Driscoll M, Gaspari AA (2011) Mycobacterium fortuitum infection following adalimumab treatment for psoriasis and subsequent complication-free treatment with alternate TNF-a blockers. J Drugs Dermatol 10(8):914–916PubMed

31.

Bordas X, Martín-Sala S (2010) Etanercept and chronic infection by HCV and HBV. Actas Dermosifiliogr 101(1):82–87PubMedCrossRef

32.

Cruz MJ, Baudrier T, Ferreira O, Azevedo F (2011) Herpes zoster at the site of infliximab infusion: case report. Cutan Ocul Toxicol 30(3):236–238PubMedCrossRef

33.

Izumi A (2009) Varicella zoster virus infection in patients taking the TNF-alpha inhibitor, etanercept: coincidence or causal? Hawaii Med J 68(11):277–278PubMed

34.

Buccoliero G, Lonero G, Romanelli C, Loperfido P, Resta F (2010) Varicella zoster virus encephalitis during treatment with anti-tumor necrosis factor-alpha agent in a psoriatic arthritis patient. New Microbiol 33(3):271–274PubMed

35.

Kelesidis T, Salhotra A, Fleisher J, Uslan DZ (2010) Listeria endocarditis in a patient with psoriatic arthritis on infliximab: are biologic agents as treatment for inflammatory arthritis increasing the incidence of Listeria infections? J Infect 60(5):386–396PubMedCrossRef

36.

Papagoras CE, Argyropoulou MI, Voulgari PV, Vrabie I, Zikou AK, Drosos AA (2009) A case of Brucella spondylitis in a patient with psoriatic arthritis receiving infliximab. Clin Exp Rheumatol 27(1):124–127PubMed

37.

Kamili QA, Menter A (2010) Atypical presentation of histoplasmosis in a patient with psoriasis and psoriatic arthritis on infliximab therapy. J Drugs Dermatol 9(1):57–60PubMed

38.

Cepeda EJ, Williams FM, Ishimori ML, Weisman MH, Reveille JD (2008) The use of anti-tumour necrosis factor therapy in HIV-positive individuals with rheumatic disease. Ann Rheum Dis 67(5):710–712PubMedCrossRef

39.

Boehncke WH, Boehncke S (2012) Cardiovascular mortality in psoriasis and psoriatic arthritis: epidemiology, pathomechanisms, therapeutic implications, and perspectives. Curr Rheumatol Rep 14(4):343–348PubMedCrossRef

40.

Di Minno MN, Iervolino S, Peluso R, Scarpa R, Di Minno G (2012) TNF-α blockers and carotid intima-media thickness: an emerging issue in the treatment of psoriatic arthritis. Intern Emerg Med 7(2):97–98CrossRef

41.

Di Minno MN, Lervolino S, Peluso R, Scarpa R, Di Minno G, CaRRDs study group (2011) Carotid intima-media thickness in psoriatic arthritis: differences between tumor necrosis factor-α blockers and traditional disease-modifying antirheumatic drugs. Arterioscler Thromb Vasc Biol 31(3):705–712PubMedCrossRef

42.

Angel K, Provan SA, Fagerhol MK, Mowinckel P, Kvien TK, Atar D (2012) Effect of 1-year anti-TNF-α therapy on aortic stiffness, carotid atherosclerosis, and calprotectin in inflammatory arthropathies: a controlled study. Am J Hypertens 25(6):644–650PubMedCrossRef

43.

Di Minno MN, Iervolino S, Lupoli R, Russolillo A, Coppola A, Peluso R, Scarpa R, Di Minno G (2012) Cardiovascular risk in rheumatic patients: the link between inflammation and atherothrombosis. Semin Thromb Hemost 38(5):497–505PubMedCrossRef

44.

Angel K, Provan SA, Hammer HB, Mowinckel P, Kvien TK, Atar D (2011) Changes in arterial stiffness during continued infliximab treatment in patients with inflammatory arthropathies. Fundam Clin Pharmacol 25(4):511–517PubMedCrossRef

45.

Channual J, Wu JJ, Dann FJ (2009) Effects of tumor necrosis factor-alpha blockade on metabolic syndrome components in psoriasis and psoriatic arthritis and additional lessons learned from rheumatoid arthritis. Dermatol Ther 22(1):61–73PubMedCrossRef

46.

Russolillo A, Iervolino S, Peluso R, Lupoli R, Di Minno A, Pappone N, Di Minno MN (2013) Obesity and psoriatic arthritis: from pathogenesis to clinical outcome and management. Rheumatology (Oxford) 52(1):62–67CrossRef

47.

Di Minno MN, Peluso R, Iervolino S, Lupoli R, Russolillo A, Scarpa R, Di Minno G (2013) Obesity and the prediction of minimal disease activity: a prospective study in psoriatic arthritis. Arthritis Care Res (Hoboken) 65(1):141–147CrossRef

48.

Ursini F, Succurro E, Grembiale A, Rudi S, Grembiale RD, Arturi F (2010) Sudden progression from impaired glucose tolerance to type 2 diabetes after discontinuation of administration of anti-tumor necrosis factor-alpha antibody infliximab. Int J Immunopathol Pharmacol 23(3):961–963PubMed

49.

Spanakis E, Sidiropoulos P, Papadakis J, Ganotakis E, Katsikas G, Karvounaris S, Bizaki A, Kritikos H, Boumpas DT (2006) Modest but sustained increase of serum high density lipoprotein cholesterol levels in patients with inflammatory arthritides treated with infliximab. J Rheumatol 33(12):2440–2446PubMed

50.

de Clari F, Salani I, Safwan E, Giannacco A (2002) Sudden death in a patient without heart failure after a single infusion of 200 mg infliximab: does TNF-α have protective effects on the failing heart, or does infliximab have direct harmful cardiovascular effects? Circulation 105:183CrossRef

51.

Kwon HJ, Cote TR, Cuffe MS, Kramer JM, Braun MM (2003) Case reports of heart failure after therapy with a tumor necrosis factor antagonist. Ann Intern Med 138(10):807–811PubMedCrossRef

52.

Mandi Y, Hogye M, Talha L et al (2000) Cytokine production and antibodies against heat shock protein 60 in cardiomyopathies of different origins. Pathobiology 68:150–158PubMedCrossRef

53.

Sanders DB, Larson DF, Hunter K et al (2001) Comparison of tumor necrosis factor-α effect on the expression of iNOS in macrophages and cardiac myocytes. Perfusion 16:67–74PubMedCrossRef

54.

Haudek SB, Bryant DD, Giroir BP (2001) Differential regulation of myocardial NK kappa B following acute or chronic TNF-α exposure. J Mol Cell Cardiol 33:1263–1271PubMedCrossRef

55.

Kadokami T, McTiernan CF, Kubota T et al (2001) Effects of soluble TNF receptor treatment on lipopolysaccharide-induced myocardial cytokine expression. Am J Physiol Heart Circ Physiol 280:2281–2291

56.

Tanaka T, Kanda T, McManus BM et al (2001) Overexpression of interleukin-6 aggravates viral myocarditis: impaired increase in tumor necrosis factor-α. J Mol Cell Cardiol 33:1627–1635PubMedCrossRef

57.

Saint Marcoux B, De Bandt M, CRI (Club Rhumatismes et Inflammation) (2006) Vasculitides induced by TNF-alpha antagonists: a study in 39 patients in France. Joint Bone Spine 73(6):710–713PubMedCrossRef

58.

Kang MJ, Kim MS, Choi EH, Lee KE, Kim YK, Choi HJ (2007) Adenoviral pneumonia during etanercept treatment in a patient with rheumatoid arthritis. Korean J Intern Med 22(1):63–66PubMedCrossRef

59.

El-Hag K, Dercken HG, Prenzel R, Hölzle E (2008) Drug-induced alveolitis associated with infliximab/azathioprine therapy. Pneumologie 62(4):204–208PubMedCrossRef

60.

Jinno S, Pulido S, Pien BC (2009) First reported United States case of Legionella pneumophila serogroup 1 pneumonia in a patient receiving anti-tumor necrosis factor-alpha therapy. Hawaii Med J 68(5):109–112PubMed

61.

Dubey S, Kerrigan N, Mills K, Scott DG (2009) Bronchospasm associated with anti-TNF treatment. Clin Rheumatol 28(8):989–992PubMedCrossRef

62.

Massara A, Cavazzini L, La Corte R, Trotta F (2010) Sarcoidosis appearing during anti-tumor necrosis factor alpha therapy: a new “class effect” paradoxical phenomenon. Two case reports and literature review. Semin Arthritis Rheum 39(4):313–319PubMedCrossRef

63.

Toussirot E, Pertuiset E, Kantelip B, Wendling D (2008) Sarcoidosis occuring during anti-TNF-alpha treatment for inflammatory rheumatic diseases: report of two cases. Clin Exp Rheumatol 26(3):471–475PubMed

64.

Daien CI, Monnier A, Claudepierre P et al (2009) Sarcoid-like granulomatosis in patients treated with tumor necrosis factor blockers: 10 cases. Rheumatology (Oxford) 48(8):883–886CrossRef

65.

Menè P, Franeta AJ, Conti G, Stoppacciaro A, Chimenz R, Fede A, Gallizzi R, Fede C (2010) Extracapillary glomerulonephritis during etanercept treatment for juvenile psoriatic arthritis. Clin Exp Rheumatol 28(1):91–93PubMed

66.

Sacquépée M, Rouleau V, Cantin JF, Quirin N, Doussy Y, Valéry JC, Picu C, Tivollier JM (2010) Active WHO class IV lupus nephritis in a patient treated with etanercept for a psoriasic arthritis. Nephrol Ther 6(6):537–540PubMedCrossRef

67.

Louie GH, Chitkara P, Ward MM (2008) Relapse of sarcoidosis upon treatment with etanercept. Ann Rheum Dis 67(6):896–898PubMedCrossRef

68.

Gonzalez-Lopez MA, Blanco R, Gonzalez-Vela MC, Fernandez-Llaca H, Rodriguez-Valverde V (2006) Development of sarcoidosis during etanercept therapy. Arthritis Rheum 55(5):817–820PubMedCrossRef

69.

O’Shea FD, Marras TK, Inman RD (2006) Pulmonary sarcoidosis developing during infliximab therapy. Arthritis Rheum 55(6):978–981PubMedCrossRef

70.

Dhaille F, Viseux V, Caudron A et al (2010) Cutaneous sarcoidosis occurring during anti-TNF-alpha treatment: report of two cases. Dermatology 220(3):234–237PubMedCrossRef

71.

Sturfelt G, Christensson B, Bynke G, Saxne T (2007) Neurosarcoidosis in a patient with rheumatoid arthritis during treatment with infliximab. J Rheumatol 34(11):2313–2314PubMed

72.

Hagel S, Bruns T, Theis B, Herrmann A, Stallmach A (2011) Subacute liver failure induced by adalimumab. Int J Clin Pharmacol Ther 49(1):38–40PubMed

73.

Sokolove J, Strand V, Greenberg JD, Curtis JR, Kavanaugh A, Kremer JM, Anofrei A, Reed G, Calabrese L, Hooper M, Baumgartner S, Furst DE, CORRONA, Investigators (2010) Risk of elevated liver enzymes associated with TNF inhibitor utilisation in patients with rheumatoid arthritis. Ann Rheum Dis 69(9):1612–1617PubMedCrossRef

74.

Ghabril M, Bonkovsky HL, Kum C, Davern T, Hayashi PH, Kleiner DE, Serrano J, Rochon J, Fontana RJ, Bonacini M, U.S. Drug-Induced Liver Injury Network (2013) Liver injury from tumor necrosis factor-α antagonists: analysis of 34 cases. Clin Gastroenterol Hepatol. doi:10.1016/j.cgh.2012.12.025

75.

Seitz M, Reichenbach S, Möller B, Zwahlen M, Villiger PM, Dufour JF (2010) Hepatoprotective effect of tumour necrosis factor alpha blockade in psoriatic arthritis: a cross-sectional study. Ann Rheum Dis 69(6):1148–1150PubMedCrossRef

76.

Massarotti M, Marasini B (2009) Successful treatment with etanercept of a patient with psoriatic arthritis after adalimumab-related hepatotoxicity. Int J Immunopathol Pharmacol 22(2):547–549PubMed

77.

Mohan N, Edwards ET, Cupps TR, Oliverio PJ, Sandberg G, Crayton H, Richert JR, Siegel JN (2001) Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritides. Arthritis Rheum 44(12):2862–2869PubMedCrossRef

78.

Sukal SA, Nadiminti L, Granstein RD (2006) Etanercept and demyelinating disease in a patient with psoriasis. J Am Acad Dermatol 54(1):160–164PubMedCrossRef

79.

Lozeron P, Denier C, Lacroix C, Adams D (2009) Long-term course of demyelinating neuropathies occurring during tumor necrosis factor-alpha-blocker therapy. Arch Neurol 66(4):490–497PubMedCrossRef

80.

Robinson WH, Genovese MC, Moreland LW (2001) Demyelinating and neurologic events reported in association with tumor necrosis factor α antagonism: by what mechanisms could tumor necrosis factor α antagonists improve rheumatoid arthritis but exacerbate multiple sclerosis? Arthritis Rheum 44(9):1977–1983PubMedCrossRef

81.

Simsek I, Erdem H, Pay S, Sobaci G, Dinc A (2007) Optic neuritis occurring with anti-tumour necrosis factor a therapy. Ann Rheum Dis 66:1255–1258PubMedCrossRef

82.

Bhatti MT, Schmitt NJ, Beatty RL (2005) Acute inflammatory demyelinating optic neuritis: current concepts in diagnosis and management. Optometry 76:526–535PubMedCrossRef

83.

Noguera-Pons R, Borras-Blasco J, Romero-Crespo I, Anton-Torres R, Navarro-Ruiz A, Gonzalez-Ferrandez JA (2005) Optic neuritis with concurrent etanercept and isoniazid therapy. Ann Pharmacother 39:2131–2135PubMedCrossRef

84.

Foroozan R, Buono LM, Sergott RC, Savino PJ (2002) Retrobulbar optic neuritis associated with infliximab. Arch Ophthalmol 120:985–987PubMed

85.

Mejico LJ (2004) Infliximab-associated retrobulbar optic neuritis. Arch Ophthalmol 122:793–794PubMedCrossRef

86.

Tauber T, Turetz J, Barash J, Avni I, Morad Y (2006) Optic neuritis associated with etanercept therapy for juvenile arthritis. J AAPOS 10:26–29PubMedCrossRef

87.

Chung JH, Van Stavern GP, Frohman LP, Turbin RE (2006) Adalimumab-associated optic neuritis. J Neurol Sci 244:133–136PubMedCrossRef

88.

Goldman AL, Braman SS (1972) Isoniazid: a review with emphasis on adverse effects. Chest 62:71–77PubMedCrossRef

89.

Van Oosten BW, Barkhof F, Truyen L, Boringa JB, Bertelsmann FW, von Blomberg BME et al (1996) Increased MRI activity and immune activation in two multiple sclerosis patients treated with the monoclonal anti-tumor necrosis factor antibody cA2. Neurology 47:1531–1534PubMedCrossRef

90.

The Lenercept Multiple Sclerosis Study Group and the University of British Columbia MS/MRI Analysis Group (1999) TNF neutralization in MS: results of a randomized, placebo-controlled multicenter study. Neurology 53:457–465CrossRef

91.

Cope A, Ettinger R, McDevitt H (1997) The role of TNF-alpha and related cytokines in the development and function of the autoreactive T-cell repertoire. Res Immunol 148:307–312PubMedCrossRef

92.

Theofilopoulos AN, Lawson BR (1999) Tumor necrosis factor and other cytokines in murine lupus. Ann Rheum Dis 58(1):149–155

93.

Kollias G, Douni E, Kassiotis G, Kontoyiannis D (1999) The function of tumor necrosis factor and receptors in models of multi-organ inflammation, rheumatoid arthritis, multiple sclerosis, and inflammatory bowel disease. Ann Rheum Dis 58(1):32–39CrossRef

94.

Cope AP, Liblau RS, Yang XD, Congia M, Laudanna C, Schreiber RD et al (1997) Chronic tumor necrosis factor alters T cell responses by attenuating T cell receptor signaling. J Exp Med 185:1573–1584PubMedCrossRef

95.

Lock C, Oksenberg J, Steinman L (1999) The role of TNFa and lymphotoxin in demyelinating disease. Ann Rheum Dis 58(1):121–128CrossRef

96.

Selmaj KW, Raine CS (1988) Tumor necrosis factor mediates myelin and oligodendrocyte damage in vitro. Ann Neurol 23:339–346PubMedCrossRef

97.

Bitsch A, Kuhlmann T, da Costa C, Bunkowski S, Polak T, Bruck W (2000) Tumour necrosis factor alpha mRNA expression in early multiple sclerosis lesions: correlation with demyelinating activity and oligodendrocyte pathology. Glia 29:366–375PubMedCrossRef

98.

Panitch HS, Hirsch RL, Haley AS, Johnson KP (1987) Exacerbations of multiple sclerosis in patients treated with gamma interferon. Lancet 1:893–895PubMedCrossRef

99.

Ramos-Casals M, Brito-Zerón P, Muñoz S, Soria N, Galiana D, Bertolaccini L, Cuadrado MJ, Khamashta MA (2007) Autoimmune diseases induced by TNF-targeted therapies: analysis of 233 cases. Medicine (Baltimore) 86(4):242–251CrossRef

100.

Costa MF, Said NR, Zimmermann B (2008) Drug-induced lupus due to anti-tumor necrosis factor alpha agents. Semin Arthritis Rheum 37(6):381–387PubMedCrossRef

101.

Levine D, Switlyk SA, Gottlieb A (2010) Cutaneous lupus erythematosus and anti-TNF-alpha therapy: a case report with review of the literature. J Drugs Dermatol 9(10):1283–1287PubMed

102.

Jarrett SJ, Cunnane G, Conaghan PG, Bingham SJ, Buch MH, Quinn MA, Emery P (2003) Anti-tumor necrosis factor-alpha therapy-induced vasculitis: case series. J Rheumatol 30(10):2287–2291PubMed

103.

Klein R, Rosenbach M, Kim EJ, Kim B, Werth VP, Dunham J (2010) Tumor necrosis factor inhibitor-associated dermatomyositis. Arch Dermatol 146(7):780–784PubMedCrossRef

104.

Mounach A, Rezqi A, Nouijai A, Ghozlani I, Achemlal L, Maghraoui AE, Bezza A (2011) Stevens-Johnson syndrome complicating adalimumab therapy in rheumatoid arthritis disease. Rheumatol Int. doi:10.1007/s00296-011-2212-4 PubMed

105.

Perez-Alvarez R, Perez-de-Lis M, Diaz-Lagares C, Pego-Reigosa JM, Retamozo S, Bove A, Brito-Zeron P, Bosch X, Ramos-Casals M (2011) Interstitial lung disease induced or exacerbated by TNF-targeted therapies: analysis of 122 cases. Semin Arthritis Rheum 41(2):256–264PubMedCrossRef

106.

Gifre L, Ruiz-Esquide V, Xaubet A, Gómez-Puerta JA, Hernández MV, Sanmartí R (2011) Lung sarcoidosis induced by TNF antagonists in rheumatoid arthritis: a case presentation and a literature review. Arch Bronconeumol 47(4):208–212PubMedCrossRef

107.

Charles PJ, Smeenk RJ, De Jong J, Feldmann M, Maini RN (2000) Assessment of antibodies to double-stranded DNA induced in rheumatoid arthritis patients following treatment with infliximab, a monoclonal antibody to tumor necrosis factor alpha: findings in open-label and randomized placebo-controlled trials. Arthritis Rheum 43:2383–2390PubMedCrossRef

108.

De Rycke L, Kruithof E, Van Damme N, Hoffman IE, Van den Bossche N, Van den Bosch F, Veys EM, De Keyser F (2003) Antinuclear antibodies following infliximab treatment in patients with rheumatoid arthritis or spondyloarthropathy. Arthritis Rheum 48(4):1015–1023PubMedCrossRef

109.

Mariette X, Tubach F, Bagheri H, Bardet M, Berthelot JM, Gaudin P et al (2010) Lymphoma in patients treated with anti-TNF: results of the 3-year prospective French RATIO registry. Ann Rheum Dis 69:400–408PubMedCrossRef

110.

Sheppard J, Raza K, Buckley CD (2007) Skin cancer in psoriatic arthritis treated with anti-TNF therapy. Rheumatology 46:1622–1623PubMedCrossRef

111.

Fryrear RS, Wiggins AK, Sangueza O, Yosipovitch G (2004) Rapid onset of cutaneous squamous cell carcinoma of the penis in a patient with psoriasis on etanercept therapy. J Am Acad Dermatol 51:1026PubMedCrossRef

112.

Rousseau A, Taberne R, Siberchicot F, Fricain JC, Zwetyenga N (2009) Cancer of the cheek in a patient under etanercept. Rev Stomatol Chir Maxillofac 110(5):306–308PubMedCrossRef

113.

Esser AC, Abril A, Fayne S, Doyle JA (2004) Acute development of multiple keratoacanthomas and squamous cell carcinomas after treatment with infliximab. J Am Acad Dermatol 50(5):75–77CrossRef

114.

Smith KJ, Skelton HG (2001) Rapid onset of cutaneous squamous cell carcinoma in patients with rheumatoid arthritis after starting tumor necrosis factor alpha receptor IgG1-Fc fusion complex therapy. J Am Acad Dermatol 45(6):953–956PubMedCrossRef

115.

Moulis G, Sommet A, Béné J, Montastruc F, Sailler L, Montastruc JL, Lapeyre-Mestre M (2012) Cancer risk of anti-TNF-α at recommended doses in adult rheumatoid arthritis: a meta-analysis with intention to treat and per protocol analyses. PLoS One 7(11):489–491CrossRef

116.

Scallon B, Cai A, Solowski N, Rosenberg A, Song XY, Shealy D et al (2002) Binding and functional comparisons of two types of tumor necrosis factor antagonists. J Pharmacol Exp Ther 301(2):418–426PubMedCrossRef

117.

Antoniou C, Kosmadaki MG, Stratigos AJ, Katsambas AD (2008) Genital HPV lesions and molluscum contagiosum occurring in patients receiving anti-TNF-alpha therapy. Dermatology 216:364–365PubMedCrossRef

118.

Santos-Juanes J, Coto-Segura P, Mallo S, Galache C, Soto J (2008) Multiple eruptive dermatofibromas in a patient receiving efalizumab. Dermatology 216:363PubMedCrossRef

119.

DeWys WD, Begg C, Lavin PT, Bandt PR, Bennett JM, Bertino JR et al (1980) Prognostic effect of weight loss prior to chemotherapy in cancer patients. Eastern Cooperative Oncology Group. Am J Med 69:491–497PubMedCrossRef

120.

Roubenoff R, Roubenoff RA, Ward LM, Holland SM, Hellmann DB (1992) Rheumatoid cachexia: depletion of lean body mass in rheumatoid arthritis. Possible association with tumor necrosis factor J Rheumatol 19:1505–1510

121.

Rall LC, Rosen CJ, Dolnikowski G, Hartman WJ, Lundgren N, Abad LW et al (1996) Protein metabolism in rheumatoid arthritis and aging. Effects of muscle strength training and tumor necrosis factor α. Arthritis Rheum 39:1115–1124PubMedCrossRef

122.

Munro R, Capell H (1997) Prevalence of low body mass in rheumatoid arthritis: association with the acute phase response. Ann Rheum Dis 56:326–329PubMedCrossRef

123.

Roubenoff R, Rall LC (1993) Humoral mediation of changing body composition during aging and chronic inflammation. Nutr Rev 51:1–11PubMedCrossRef

124.

Westhovens R, Nijs J, Taelman V, Dequeker J (1997) Body composition in rheumatoid arthritis. Br J Rheumatol 36:444–448PubMedCrossRef

125.

Coppack SW (2001) Pro-inflammatory cytokines and adipose tissue. Proc Nutr Soc 60:349–356PubMedCrossRef

126.

Briot K, Garnero P, Le Henanff A, Dougados M, Roux C (2005) Body weight, body composition, and bone turnover changes in patients with spondyloarthropathy receiving anti-tumour necrosis factor a treatment. Ann Rheum Dis 64:1137–1140PubMedCrossRef

127.

Allali F, Breban M, Porcher R, Maillefert JF, Dougados M, Roux C (2003) Increase in bone mineral density of patients with spondylarthropthy treated with antitumour necrosis factor alpha. Ann Rheum Dis 62:347–349PubMedCrossRef

128.

Lutf A, Hammoudeh M (2012) Weight gain and hair loss during anti-TNF therapy. Int J Rheumatol. doi:10.1155/2012/593039 PubMed

129.

Renzo LD, Saraceno R, Schipani C, Rizzo M, Bianchi A, Noce A, Esposito M, Tiberti S, Chimenti S, DE Lorenzo A (2011) Prospective assessment of body weight and body composition changes in patients with psoriasis receiving anti-TNF-α treatment. Dermatol Ther 24(4):446–451PubMedCrossRef

130.

Seriolo B, Paolino S, Sulli A, Cutolo M (2006) Are there any positive effects of TNF-alpha blockers on bone metabolism? Reumatismo 58(3):199–205PubMed

131.

Ferran M, Calvet J, Almirall M, Pujol RM, Maym J (2011) Alopecia areata as another immune-mediated disease developed in patients treated with tumor necrosis factor-α blocker agents. J Eur Acad Dermatol Venereol 25(4):479–484PubMedCrossRef

132.

Daher S, Fonseca F, Ribero O, Musatti C, Gerbase de Lima M (1999) Tumor necrosis factor during pregnancy. Eur J Obstet Gyn R B 83:77–79CrossRef

133.

Yu XW, Yan CF, Jin HL, Li X (2005) Tumor necrosis factor receptor 1 expression and early spontaneous abortion. Int J Gynecol and Obstet 88:44–44CrossRef

134.

Chambers CD (2005) Safety of anti-TNF alpha medications in pregnancy. J Am Acad Dermatol 52(2):155–08

135.

Chakravarty EF, Sanchez-Yamamoto D, Bush TE (2003) The use of disease modifying anti-rheumatic drugs in women with rheumatoid arthritis of child bearing age: a survey of practice patterns and pregnancy outcomes. J Rheumatol 30:241–246PubMed

136.

Joven BE, Garcia-Gonzales AJ, Ruiz T et al (2005) Pregnancy in women receiving anti TNF therapy. Experience in Spain. Arthritis Rheum 52:S349CrossRef

137.

Carter JD, Valeriano J, Vasey B (2006) Tumor necrosis factor alpha inhibition and VATER association: a causal relationship? J Rheumatol 33:1014–1017PubMed

138.

Roux CH, Brocq O, Breuil V, Albert C, Euller-Ziegler L (2007) Pregnancy in rheumatology patients exposed to anti-tumour necrosis factor (TNF)-α therapy. Rheumatology 46:695–698PubMedCrossRef

139.

Berthelot JM, De Bandt M, Goupille P, Solau-Gervais E, Lioté F, Goeb V, Azaïs I, Martin A, Pallot-Prades B, Maugars Y, Mariette X, CRI (Club Rhumatismes et Inflammation) (2009) Exposition to anti-TNF drugs during pregnancy: outcome of 15 cases and review of the literature. Joint Bone Spine 76(1):28–34PubMedCrossRef

140.

Giroir BP, Peppel K, Siva M, Beutler B (1992) The biosynthesis of tumor necrosis factor during pregnancy: studies with a CAT reporter transgene and TNF inhibitors. Eur Cytokine Netw 3:533–537PubMed

141.

Treacy G (2000) Using an autologous monoclonal antibody to evaluate the reproductive and chronic toxicity potential for a humanized anti TNF alpha monoclonal antibody. Hum Exp Toxicol 19:226–228PubMedCrossRef

Title: Side effects of TNF-α blockers in patients with psoriatic arthritis: evidences from literature studies
Authors: Rosario Peluso
Giovanni Cafaro
Alessandro Di Minno
Salvatore Iervolino
Pasquale Ambrosino
Gelsy Lupoli
Matteo Nicola Dario Di Minno
Publication date: 01-06-2013
Publisher: Springer-Verlag
Published in: Clinical Rheumatology / Issue 6/2013
Print ISSN: 0770-3198
Electronic ISSN: 1434-9949
DOI: https://doi.org/10.1007/s10067-013-2252-0

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 6/2013

Systemic lupus erythematosus-related pancreatitis in children

Hydrochloroquine retinopathy: characteristic presentation with review of screening

Organ involvement in Argentinian systemic sclerosis patients with “late” pattern as compared to patients with “early/active” pattern by nailfold capillaroscopy

Aggrecanases in the human synovial fluid at different stages of osteoarthritis

The effect of vitamin D levels on the assessment of disease activity in rheumatoid arthritis

New-onset systemic lupus erythematosus during pregnancy

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials